-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TOuUvL1n1FWyN5Zrc1nPzHuEziYvY3+uai4sRk7m3Kujmzn/FFkzoBV2NuVUPb7w TXm2R0h8KYq5kCtslN2pcw== 0001012870-01-501723.txt : 20010827 0001012870-01-501723.hdr.sgml : 20010827 ACCESSION NUMBER: 0001012870-01-501723 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20010823 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20010824 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIDAMED INC CENTRAL INDEX KEY: 0000929900 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 770314454 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26082 FILM NUMBER: 1722330 BUSINESS ADDRESS: STREET 1: 46107 LANDING PARKWAY STREET 2: SUITE 101 CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: 5104924900 MAIL ADDRESS: STREET 1: 46107 LANDING PARKWAY STREET 2: STE 101 CITY: FREMONT STATE: CA ZIP: 94538 8-K 1 d8k.txt FORM 8-K ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 __________________ Date of Report (Date of earliest event reported): August 23, 2001 ___________________ VIDAMED, INC. (Exact name of registrant as specified in its charter) Delaware 0-26082 77-0314454 (State or Other Jurisdiction of (Commission File Number) (I.R.S. Employer Incorporation) Identification Number) 46107 Landing Parkway Fremont, California 94538 (Address of Principal Executive Offices) (Zip Code) (510) 492-4900 (Registrant's Telephone Number, Including Area Code) N/A (Former Name or Former Address, If Changed Since Last Report) ================================================================================ Item 5. Other Events On August 23, 2001, VidaMed, Inc. announced that Randy D. Lindholm, Chairman, President and Chief Executive Officer of VidaMed, adopted a written trading plan pursuant to Rule 10b5-1 under the Securities Act of 1934 that will allow him to sell up to 15,000 shares of VidaMed stock a month. Mr. Lindholm currently holds over 2.1 million shares of VidaMed stock, including stock options. A copy of the press release announcing the plan is attached to this report as Exhibit 99.1 and is incorporated herein by this reference. Item 7. Financial Statements and Exhibits. (c) Exhibits. Exhibit No. Description ------- ------------------------------------ 99.1 Press Release issued August 23, 2001 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIDAMED, INC. By: /s/ Randy D. Lindholm --------------------------- Randy D. Lindholm Chairman, President and Chief Executive Officer Dated: August 23, 2001 VIDAMED, Inc. FORM 8-K Exhibit Index ------------- Exhibit No. Description Method of Filing ------- ------------------------------------ ---------------- 99.1 Press Release issued August 23, 2001 Filed herewith EX-99.1 3 dex991.txt PRESS RELEASE ISSUED AUGUST 23, 2001 Exhibit 99.1 Company Contacts Investor Contacts VidaMed, Inc. Lippert Heilshorn & Associates - ------------- Bruce Voss (Bvoss@lhai.com) Randy Lindholm, Chairman, President & CEO Martin Halsall (Mhalsall@lhai.com) John Howe, Chief Financial Officer (310) 691-7100 (510) 492-4900 www.vidamed.com - --------------- VIDAMED CEO ADOPTS INSIDER TRADING PLAN FREMONT, Calif. (August 23, 2001) - VidaMed, Inc. (NASDAQ: VIDA) today announced that Randy Lindholm, chief executive officer, adopted a trading plan that will allow him to sell up to 15,000 shares of VidaMed stock a month under a government-approved insider trading rule that allows corporate insiders to systematically buy or sell stock. "The establishment of this trading plan is designed to allow me to diversify my portfolio by exercising a small portion of my VidaMed options and selling the underlying shares in the open market. In the past, I have been unable to do this due to the legal concerns involved since I frequently possess at any given time material, nonpublic information about VidaMed," Lindholm stated. The Securities and Exchange Commission's Rule 10b5-1 allows corporate insiders to establish prearranged programs to sell or purchase a Company's securities based on criteria prescribed by the insider. The programs are prepared at a time when that individual is not aware of any material non-public information. The predetermined selling programs are designed to remove much of the discretionary aspects of periodic diversification so as to alleviate potential misperceptions of insider trading. Lindholm currently holds over 2.1 million shares of VidaMed stock, including stock options. VidaMed designs, develops and markets technologically and clinically advanced cost-effective systems for the treatment of urological conditions. For investor information, please call (800) 363-2994 or visit VidaMed's Web site at www.vidamed.com. - --------------- Certain statements in this news release contain forward-looking information. Actual results may vary significantly from those anticipated in such forward- looking statements due to risks and uncertainties, including risks described in VidaMed's reports filed from time to time with the United States Securities and Exchange Commission. # # # -----END PRIVACY-ENHANCED MESSAGE-----